DexCom, Inc. - Common Stock (NQ:DXCM)

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be...

Topics Earnings Economy

Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall ↗

February 12, 2026

Via Chartmill

DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations

February 12, 2026

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need to know.

Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow

February 10, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Topics Artificial Intelligence

DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern ↗

January 20, 2026

Via Chartmill

1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore

February 08, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

February 05, 2026

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

3 Profitable Stocks for Long-Term Investors

January 28, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

January 26, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

Topics Economy

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

It has had strong momentum since November, but there is still plenty of upside left.

Topics Earnings Economy

1 Growth Stock Down 19% to Buy Right Now ↗

January 21, 2026

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the...

Topics Product Recall

Top S&P500 movers in Monday's session ↗

January 12, 2026

Via Chartmill

What's going on in today's session: S&P500 movers ↗

January 12, 2026

Via Chartmill

DexCom (DXCM) Stock Trades Down, Here Is Why

January 08, 2026

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance...

Topics Artificial Intelligence

3 Nasdaq 100 Stocks Worth Your Attention

January 04, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

Via PredictStreet

Topics Economy Lawsuit World Trade

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Neither had a great year in 2025, but the future is looking bright.

Topics Stocks

2 Growth Stocks to Buy For 2026 and Beyond ↗

December 30, 2025

DexCom (DXCM) exemplifies Growth at a Reasonable Price (GARP) with strong double-digit earnings growth, solid profitability, and a valuation justified by its industry-leading position in diabetes...

Topics Economy

DexCom Inc (NASDAQ:DXCM) Embodies the Growth at a Reasonable Price (GARP) Strategy ↗

December 30, 2025

Via Chartmill

The $65 Billion Pulse: How Wearable AI and Telemedicine are Redefining the Future of Healthcare

December 24, 2025

The convergence of consumer technology and clinical medicine has reached a fever pitch as 2025 draws to a close. A landmark report released this December by ResearchAndMarkets.com projects that the...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Topics Artificial Intelligence

1 Cash-Heavy Stock for Long-Term Investors and 2 We Avoid

December 22, 2025

DexCom (DXCM) combines strong growth fundamentals with a promising technical breakout setup, offering a potential entry point for investors.

DexCom Inc (NASDAQ:DXCM): A High-Growth Stock Forming a Bullish Technical Setup ↗

December 19, 2025

Via Chartmill

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Ignore

December 18, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

“Buying the Dip” in 2025: A Strategy Rewarded, But Future Requires Caution and Diversification

December 16, 2025

December 16, 2025 – The "buying the dip" investment strategy, which involves purchasing an asset after its price has declined with the anticipation of a subsequent recovery, has seen significant...

Navigating Nuance: Tech Innovation, Healthcare Revival, and Energy's Evolving Landscape Shape Late 2025 Markets

Topics Artificial Intelligence Economy

December 11, 2025

As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by...

DexCom (DXCM) exemplifies the GARP strategy, offering strong revenue & earnings growth, high profitability, and a reasonable valuation within its high-growth industry.

Topics Artificial Intelligence Economy Electric Vehicles

DexCom Inc (NASDAQ:DXCM) Emerges as a Top Affordable Growth Stock ↗

December 05, 2025

Via Chartmill

3 Mid-Cap Stocks to Research Further

December 03, 2025

Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses...

Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.

If you're investing for the next 30 years, don't overlook these top stocks.

Topics Economy Government

2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon ↗

November 23, 2025